CVLLY (CellaVision AB) Long-Term Debt: $1.11 Mil (As of Mar. 2026)


CVLLY CellaVision AB CVLLY
69 GF Score
Price $7.06
GF Value $12.48
Valuation Significantly Undervalued
! 1 Warning Sign
View Full Analysis

What is CellaVision AB Long-Term Debt?

CellaVision AB CVLLY +12.06% 69 Long-Term Debt is $1.11 Mil as of Mar. 2026. GuruFocus rates CVLLY with a GF Score™ of 69/100 and a GF Value™ of $12.48 (Significantly Undervalued). The stock has 1 warning sign investors should review.

CellaVision AB's Long-Term Debt for the quarter that ended in Mar. 2026 was $1.11 Mil.

CellaVision AB's quarterly Long-Term Debt declined from Sep. 2025 ($1.42 Mil) to Dec. 2025 ($1.29 Mil) and declined from Dec. 2025 ($1.29 Mil) to Mar. 2026 ($1.11 Mil).

CellaVision AB's annual Long-Term Debt declined from Dec. 2023 ($2.79 Mil) to Dec. 2024 ($1.15 Mil) but then increased from Dec. 2024 ($1.15 Mil) to Dec. 2025 ($1.29 Mil).

CellaVision AB  (OTCPK:CVLLY) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

CellaVision AB Long-Term Debt Related Terms

CellaVision AB Long-Term Debt Historical Data

* Premium members only.

The historical data trend for CellaVision AB's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CellaVision AB Long-Term Debt Chart

CellaVision AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.54 5.82 2.79 1.15 1.29

CellaVision AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.89 1.53 1.42 1.29 1.11
CVLLY
69GF Score
CellaVision AB CVLLY
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $1.11 Mil mean?
CellaVision AB (CVLLY) has a Long-Term Debt of $1.11 Mil as of Mar. 2026.
Is CellaVision AB's Long-Term Debt too high?
CellaVision AB's current Long-Term Debt is $1.11 Mil. Overall, CellaVision AB has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CellaVision AB's Long-Term Debt compare to ABT and SYK?
CellaVision AB's Long-Term Debt of $1.11 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Medical Devices & Instruments company?
A good Long-Term Debt depends on the Medical Devices & Instruments industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. CellaVision AB's current Long-Term Debt is $1.11 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CellaVision AB stock overvalued right now?
Based on GuruFocus' analysis, CellaVision AB (CVLLY) is currently considered Significantly Undervalued. The stock's GF Value™ is $12.48, compared to a current price of $7.06 — trading 43.4% below its estimated fair value. The current Long-Term Debt is $1.11 Mil. CellaVision AB's overall GF Score™ is 69/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For CellaVision AB (CVLLY), the current Long-Term Debt is $1.11 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CellaVision AB (CVLLY) Overvalued in 2026?

Based on GuruFocus' analysis, CellaVision AB stock appears to be undervalued. The current stock price of $7.06 is trading 43.4% below its estimated GF Value™ of $12.48. GuruFocus considers CellaVision AB to be Significantly Undervalued.

Key valuation signals for CVLLY:

  • Long-Term Debt: $1.11 Mil
  • GF Value™: $12.48 vs. price of $7.06 (43.4% below fair value)
  • GF Score™: 69/100 with 1 warning sign

No single metric tells the full story. See the CVLLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CellaVision AB Business Description

Address Mobilvagen 12, Lund, SWE, 22362
CellaVision AB is engaged in developing and selling instruments, software, and reagents for blood and body fluid analysis. The company automates parts of the sample preparation process and replaces manual microscopes with instruments based on digital image analysis technology and artificial intelligence. The solutions contribute to more effective workflows and higher quality in laboratory medicine. The product offer consists of products and solutions for standardized laboratory diagnostics and improved performance for cellular image processing and systems for digital microscopy in hematology, consisting of reagents, instruments, and supplementary software and peripheral equipment.
69GF Score

Get the complete analysis for CVLLY

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.06
Price
$12.48
GF Value